Cristina Royo-Cebrecos1, Ïa Robert-Montaner2, David Vilanova3, Eva Bailles4, Jordi Serrano-Pons5, Oliver Valero6, Josep Maria Buldon7, Leticia Bermudez-de-Castro8, Eva Mahia9, Jaume Pujadas9, Francesc Cobo10, Josep Maria Piqué11, Santiago Albiol9. 1. Department of Internal Medicine, Hospital Nostra Senyora de Meritxell, Andorra Andorra Health Services (SAAS), Av. Fiter i Rosell 1-13, AD700, Escaldes-Engordany, Andorra. croyo@saas.ad. 2. University of Nottingham Medical School, Queens Medical Centre, Nottingham, UK. 3. National Laboratory, SAAS, Escaldes-Engordany, Andorra. 4. Psychology Department, Hospital Nostra Senyora de Meritxell, SAAS, Escaldes-Engordany, Andorra. 5. Founder of UniversalDoctor: The Digital Global Health Company, Barcelona, Spain. 6. Servei d'Estadística Aplicada, Universitat Autònoma de Barcelona. Cerdanyola del Vallès, Barcelona, Spain. 7. Biostatistics, Hospital Nostra Senyora de Meritxell, SAAS, Escaldes-Engordany, Andorra. 8. Clinical Laboratory Department, Hospital Nostra Senyora de Meritxell, SAAS, Escaldes-Engordany, Andorra. 9. Oncology Department of Hospital Nostra Senyora de Meritxell, SAAS, Escaldes-Engordany, Andorra. 10. Hematology Department of Hospital Nostra Senyora de Meritxell, SAAS, Escaldes-Engordany, Andorra. 11. Andorra Health Services (SAAS), Escaldes-Engordany, Andorra.
Abstract
BACKGROUND: COVID-19 serologic response in patients with cancer may be lower than in the general population and may be influenced by the type of tumor or anticancer treatment. This study aims to analyze serological response prior and after vaccination of COVID-19 within the oncological population in Andorra. We set out to identify risk factors for a higher or lower serological response. PATIENTS AND METHODS: Observational, unicentric, prospective cohort study of oncologic patients in Andorra. We calculated the seroprevalence of antibodies against SARS-CoV-2 (May 2020-June 2021) and analyzed the main demographic, oncologic features and factors associated with being seropositive. RESULTS: A total of 373 patients were analyzed, mainly with solid tumours (n = 334, 89.5%). At baseline, seroprevalence was 13%, increasing during follow-up to 19%; lower seroprevalence was observed in patients with hematologic malignancies (2.6% vs 14.2%; p = 0.041) and patients receiving biological therapies (0% vs 15%, p = 0.005). In the overall seroprevalence analysis, women (23% vs 11.9%; p = 0.006) and tumour-free patients (p = 0.034) showed higher seroprevalence. The multivariable analysis showed that odds of being seropositive were higher among women (OR: 2.44, 95% CI 1.28-4.64), and patients who underwent surgery (OR: 3.35, 95% CI 1.10-10.20). About 80% of the cohort received at least one dose of COVID-19 vaccination, showing a higher seroprevalence of patients who received ChAdOx1-S than those who received BNT162b2 (24.4% vs 6.4%: p = 0.001). CONCLUSION: The seroprevalence of antibodies against SARS-COV-2 in oncologic patients in Andorra was higher among females and patients who received hormonal therapy and surgery while patients with hematologic malignancies and biologic therapies showed lower seropositivity without finding differences in the type of tumour or anticancer treatment.
BACKGROUND: COVID-19 serologic response in patients with cancer may be lower than in the general population and may be influenced by the type of tumor or anticancer treatment. This study aims to analyze serological response prior and after vaccination of COVID-19 within the oncological population in Andorra. We set out to identify risk factors for a higher or lower serological response. PATIENTS AND METHODS: Observational, unicentric, prospective cohort study of oncologic patients in Andorra. We calculated the seroprevalence of antibodies against SARS-CoV-2 (May 2020-June 2021) and analyzed the main demographic, oncologic features and factors associated with being seropositive. RESULTS: A total of 373 patients were analyzed, mainly with solid tumours (n = 334, 89.5%). At baseline, seroprevalence was 13%, increasing during follow-up to 19%; lower seroprevalence was observed in patients with hematologic malignancies (2.6% vs 14.2%; p = 0.041) and patients receiving biological therapies (0% vs 15%, p = 0.005). In the overall seroprevalence analysis, women (23% vs 11.9%; p = 0.006) and tumour-free patients (p = 0.034) showed higher seroprevalence. The multivariable analysis showed that odds of being seropositive were higher among women (OR: 2.44, 95% CI 1.28-4.64), and patients who underwent surgery (OR: 3.35, 95% CI 1.10-10.20). About 80% of the cohort received at least one dose of COVID-19 vaccination, showing a higher seroprevalence of patients who received ChAdOx1-S than those who received BNT162b2 (24.4% vs 6.4%: p = 0.001). CONCLUSION: The seroprevalence of antibodies against SARS-COV-2 in oncologic patients in Andorra was higher among females and patients who received hormonal therapy and surgery while patients with hematologic malignancies and biologic therapies showed lower seropositivity without finding differences in the type of tumour or anticancer treatment.
Authors: Cristina Royo-Cebrecos; David Vilanova; Joel López; Vanesa Arroyo; Marc Pons; Guillem Francisco; Mireia G Carrasco; Josep M Piqué; Sergi Sanz; Carlota Dobaño; Alberto L García-Basteiro Journal: Lancet Reg Health Eur Date: 2021-05-21
Authors: Kamal S Saini; Marco Tagliamento; Matteo Lambertini; Richard McNally; Marco Romano; Manuela Leone; Giuseppe Curigliano; Evandro de Azambuja Journal: Eur J Cancer Date: 2020-09-02 Impact factor: 9.162